We were pleased to welcome Natalya Serbina, Senior Director at TB Alliance, to Archivel as part of our ongoing collaboration within the international Host Directed Therapy in Tuberculosis project.
This joint initiative focuses on exploring how the RUTI® vaccine, developed by Archivel, can enhance the efficacy of next-generation antibiotics in the treatment of tuberculosis. By combining immunotherapeutic approaches with advanced antibiotic regimens, the project aims to improve treatment outcomes and pave the way for innovative strategies in the global fight against tuberculosis.
Natalya’s visit provided an excellent opportunity to share insights on our progress and discuss future steps in this promising line of research. We are grateful for her visit and look forward to strengthening our collaboration as we work together to advance tuberculosis treatment innovation.